company background image
BRSY.F logo

BrainsWay OTCPK:BRSY.F Stock Report

Last Price

US$8.53

Market Cap

US$181.4m

7D

0%

1Y

n/a

Updated

10 Jan, 2025

Data

Company Financials +

BrainsWay Ltd.

OTCPK:BRSY.F Stock Report

Market Cap: US$181.4m

BRSY.F Stock Overview

Develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. More details

BRSY.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 82% below our estimate of its fair value

Earnings are forecast to grow 64.63% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year


My Notes

Capture your thoughts, links and company narrative

BrainsWay Ltd. Competitors

Kewaunee Scientific

NasdaqGM:KEQU

US$176.0m

Baird Medical Investment Holdings

NasdaqCM:BDMD

US$273.7m

Pro-Dex

NasdaqCM:PDEX

US$162.0m

Jin Medical International

NasdaqCM:ZJYL

US$133.1m

Price History & Performance

Summary of share price highs, lows and changes for BrainsWay
Historical stock prices
Current Share Price₪8.53
52 Week High₪8.53
52 Week Low₪1.85
Beta0.40
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Change69.48%
Change since IPO610.42%

Recent News & Updates

Recent updates

Shareholder Returns

BRSY.FUS Medical EquipmentUS Market
7D0%1.0%-2.1%
1Yn/a8.5%21.3%

Return vs Industry: Insufficient data to determine how BRSY.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how BRSY.F performed against the US Market.

Price Volatility

Is BRSY.F's price volatile compared to industry and market?
BRSY.F volatility
BRSY.F Average Weekly Movementn/a
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.4%
10% most volatile stocks in US Market18.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: BRSY.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BRSY.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003134Hadar Levywww.brainsway.com

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry.

BrainsWay Ltd. Fundamentals Summary

How do BrainsWay's earnings and revenue compare to its market cap?
BRSY.F fundamental statistics
Market capUS$181.35m
Earnings (TTM)US$1.50m
Revenue (TTM)US$38.63m

120.9x

P/E Ratio

4.7x

P/S Ratio

Is BRSY.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BRSY.F income statement (TTM)
RevenueUS$38.63m
Cost of RevenueUS$9.82m
Gross ProfitUS$28.81m
Other ExpensesUS$27.31m
EarningsUS$1.50m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.04
Gross Margin74.57%
Net Profit Margin3.88%
Debt/Equity Ratio0%

How did BRSY.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 07:32
End of Day Share Price 2024/12/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BrainsWay Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle MiksonCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.
Jeffrey CohenLadenburg Thalmann & Company